三阴性乳腺癌组织乳腺癌易感基因1与表皮生长因子受体的表达及临床意义
摘要
目的探讨乳腺癌易感基因1(BRCA1)和表皮生长因子受体(EGFR)在三阴性乳腺癌组织中的表达、临床意义及相关性。方法收集51例三阴性乳腺癌标本,用高通量测序及免疫组化技术检测BRCA1突变和EGFR的表达,比较不同临床病理特征的三阴性乳腺癌患者癌组织中BRCA1突变与EGFR的表达。结果 BRCA1突变患者发病年龄较小、淋巴结转移率较高,临床分期较晚(P<0.05);EGFR在肿块最大径>2 cm、有淋巴结转移、临床分期Ⅲ～Ⅳ期患者组织中阳性表达率较高(P<0.05);BRCA1与EGFR具有相关性(P<0.05)。结论检测三阴性乳腺癌患者BRCA1及EGFR,对指导治疗及评价预后有重要的临床意义。
引文
[1] 吴志懂,覃俊仕.BRCA-1基因与三阴性乳腺癌的研究进展[J].世界临床医学,2016,10(17):121-122.
[2] 冯传宝.EGFR与VEGF在三阴性乳腺癌中的表达及意义[J].中国现代医生,2017,55(14):32-34,37.
[3] Elsamany S,Abdullah S.Triple-negative breast cancer:future prospects in diagnosis and management[J].Medical Oncology,2014,31(2):834.
[4] Dutta P R,Maity A.Cellular responses to EGFR inhibitors and their relevance to cancer therapy[J].Cancer Letters,2007,254(2):165-177.
[5] Association Between BRCA Status and Triple-Negative Breast Cancer:A Meta-Analysis[J].Frontiers in Pharmacology,2018,9:909.
[6] Soto J A D,Deng C X.PARP-1 inhibitors:are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers[J].International Journal of Medical Sciences,2006,3(4):117-123.
[7] Robson M,Im S A,Senkus E,et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J].New England Journal of Medicine,2017,377(6):523.
[8] Danzinger S,Tan Y Y,Rudas M,et al.Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer[J].Cancer Investigation,2018(2):1-11.
[9] 黄羽,黄克强.结直肠癌组织乳腺癌易感基因1与表皮生长因子受体的蛋白表达及其临床意义[J].广西医学,2017,39(1):35-38.
[2] 冯传宝.EGFR与VEGF在三阴性乳腺癌中的表达及意义[J].中国现代医生,2017,55(14):32-34,37.
[3] Elsamany S,Abdullah S.Triple-negative breast cancer:future prospects in diagnosis and management[J].Medical Oncology,2014,31(2):834.
[4] Dutta P R,Maity A.Cellular responses to EGFR inhibitors and their relevance to cancer therapy[J].Cancer Letters,2007,254(2):165-177.
[5] Association Between BRCA Status and Triple-Negative Breast Cancer:A Meta-Analysis[J].Frontiers in Pharmacology,2018,9:909.
[6] Soto J A D,Deng C X.PARP-1 inhibitors:are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers[J].International Journal of Medical Sciences,2006,3(4):117-123.
[7] Robson M,Im S A,Senkus E,et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J].New England Journal of Medicine,2017,377(6):523.
[8] Danzinger S,Tan Y Y,Rudas M,et al.Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer[J].Cancer Investigation,2018(2):1-11.
[9] 黄羽,黄克强.结直肠癌组织乳腺癌易感基因1与表皮生长因子受体的蛋白表达及其临床意义[J].广西医学,2017,39(1):35-38.